| Extranodal diffuse large B cell lymphoma: molecular features, prognosis, and risk of central nervous system recurrence TA Ollila, AJ Olszewski Current treatment options in oncology 19, 1-20, 2018 | 146 | 2018 |
| Antibody response to COVID-19 vaccination in adults with hematologic malignant disease TA Ollila, S Lu, R Masel, A Zayac, K Paiva, RD Rogers, AJ Olszewski JAMA oncology 7 (11), 1714-1716, 2021 | 70 | 2021 |
| Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma TA Ollila, I Sahin, AJ Olszewski OncoTargets and therapy, 1085-1094, 2019 | 65 | 2019 |
| Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions VM Orellana-Noia, DR Reed, AA McCook, JM Sen, CM Barlow, ... Blood, The Journal of the American Society of Hematology 139 (3), 413-423, 2022 | 61 | 2022 |
| Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma TA Ollila, H Kurt, J Waroich, J Vatkevich, A Sturtevant, NR Patel, ... Blood, The Journal of the American Society of Hematology 137 (8), 1120-1124, 2021 | 42 | 2021 |
| Seroconversion and outcomes after initial and booster COVID‐19 vaccination in adults with hematologic malignancies TA Ollila, RH Masel, JL Reagan, S Lu, RD Rogers, KJ Paiva, R Taher, ... Cancer 128 (18), 3319-3329, 2022 | 32 | 2022 |
| Time to treatment is an independent prognostic factor in aggressive non‐Hodgkin lymphomas AJ Olszewski, T Ollila, JL Reagan British journal of haematology 181 (4), 495-504, 2018 | 28 | 2018 |
| Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma AJ Olszewski, AD Chorzalska, M Petersen, TA Ollila, A Zayac, H Kurt, ... Blood advances 5 (24), 5525-5535, 2021 | 21 | 2021 |
| CNS prophylaxis during front-line therapy in aggressive non-Hodgkin lymphomas: real-world outcomes and practice patterns from 19 US academic institutions VM Orellana-Noia, DR Reed, JM Sen, C Barlow, MK Malecek, BS Kahl, ... Blood 136, 27-28, 2020 | 16 | 2020 |
| Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL J Zurko, I Nizamuddin, N Epperla, K David, JB Cohen, TK Moyo, T Ollila, ... Blood Advances 7 (12), 2657-2669, 2023 | 14 | 2023 |
| Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base TA Ollila, JL Reagan, AJ Olszewski Leukemia & lymphoma 60 (14), 3426-3433, 2019 | 11 | 2019 |
| Outcomes and treatment patterns in patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy JC Zurko, N Epperla, I Nizamuddin, P Torka, KA David, TA Ollila, BT Hess, ... Blood 138, 884, 2021 | 10 | 2021 |
| Exposure to ibritumomab tiuxetan and incidence of treatment-related myeloid neoplasms among older patients with B-cell lymphoma: a population-based study M Di, TA Ollila, AJ Olszewski Leukemia 34 (10), 2794-2797, 2020 | 10 | 2020 |
| Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 US cancer centers KA David, S Sundaram, SH Kim, R Vaca, Y Lin, S Singer, MK Malecek, ... American journal of hematology 98 (6), 900-912, 2023 | 9 | 2023 |
| Chemotherapy-free management of follicular and marginal zone lymphoma TA Ollila, AJ Olszewski Cancer Management and Research, 3935-3952, 2021 | 9 | 2021 |
| Radiation therapy in primary testicular lymphoma: does practice match the standard of care? TA Ollila, AJ Olszewski Leukemia & lymphoma 60 (2), 523-526, 2019 | 7 | 2019 |
| Marrow hypocellularity, but not residual blast count or receipt of reinduction chemotherapy, is prognostic on day-14 assessment in acute myeloid leukemia patients with … TA Ollila, AJ Olszewski, JN Butera, MI Quesenberry, PJ Quesenberry, ... Clinical Lymphoma Myeloma and Leukemia 18 (3), 204-209, 2018 | 7 | 2018 |
| Analysis of hematology and oncology fellowship website content and diversity representation A Muthiah, V Aggarwal, C Muthiah, C Wei, T Ollila, MI Quesenberry, ... JCO Oncology Practice 18 (4), e600-e609, 2022 | 6 | 2022 |
| Bendamustine-rituximab does not improve survival over rituximab monotherapy for older patients with nodal or splenic marginal zone lymphoma AJ Olszewski, TA Ollila, JL Reagan Blood 134, 2824, 2019 | 6 | 2019 |
| Embolization of inferior vena cava filter tyne and right ventricular perforation: a cardiac missile T Ollila, S Naeem, A Poppas, G McKendall, A Ehsan The Annals of Thoracic Surgery 102 (6), e515-e516, 2016 | 6 | 2016 |
Adam OlszewskiAssociate Professor, Brown University Alpert Medical SchoolVerified email at brown.edu
